Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dedicated US diabetes "post" warranted:

This article was originally published in Clinica

Executive Summary

Some 12% of US federal healthcare spending goes towards diabetes treatment, says a National Changing Diabetes Program (NCDP) study, conducted by Mathematica Policy Research, that was profiled to the Congressional Diabetes Caucus on June 19. The sheer cost of the problem means that a government post should be created to oversee the spending on treatment and prevention among federal agencies. Using 2005 data, the study found that diabetics cost $80bn more to treat than non-diabetics - in a budget of $645bn that year. 18 out of the 21 federal agencies (ie not just HHS) have a budgetary impact on diabetes, it is claimed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048934

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel